SAN ANTONIOMarked reductions in breast cancer recurrence were achieved with a shorter standard adjuvant chemotherapy regimen, augmented by weekly doses of paclitaxel, in a study by the Spanish Group for Breast Cancer Research, the GEICAM 9906 trial, presented at the 28th Annual San Antonio Breast Cancer Symposium (abstract 39).
The first interim analysis also showed an improvement in disease-free survival (DFS), and similar benefits in all subgroups, according to Miguel Martin, MD, PhD, of Hospital Universitario San Carlos, Madrid, Spain.
GEICAM 9906 included 1,248 patients with operable breast cancer randomized to the experimental armfour cycles of fluorouracil (600 mg/m2), epirubicin (90 mg/m2), and cyclophosphamide (600 mg/m2) (FEC) followed by paclitaxel 100 mg/m2 weekly for 8 weeksor to FEC given for six cycles, a standard adjuvant regimen. Total treatment duration was 15 weeks for the experimental regimen vs 17 weeks for the standard arm.
Additionally, tamoxifen was given for 5 years to women with hormone-receptor-positive tumors (76% to 82%), and radiotherapy was administered according to the individual center's guidelines (70% to 71%).
The interim analysis was triggered after 211 recurrences, with a median follow-up of 46 months. Of these 211 events, 128 were in the control arm and 83 in the experimental arm. Breast cancer relapses accounted for 120 and 68 of these, respectively; second malignancies and contralateral breast cancers numbered 7 and 11; and deaths from other causes totaled 1 and 4, respectively.
These outcomes yielded a disease-free survival rate of 79% vs 85%, respectively. FEC plus paclitaxel resulted in a 37% reduction in the risk of recurrence, after controlling for nodes, age, tumor size, histology, hormone-receptor status, and tamoxifen use. This difference was highly significant (P = .0008), Dr. Martin said.
"FEC followed by paclitaxel did better in all subgroups of patients," he said. Subsets included patients with 1 to 3 positive nodes and 4+ positive nodes, pre- and postmenopausal status, hormone-receptor-positive and hormone-receptor-negative status, and HER2 3+ and 0 to 2+ positivity.